Can Jisandai/Bingtonsha completely cure hepatitis C?

Epclusa is a highly effective antiviral drug currently widely used in the treatment of hepatitis C internationally. It consists of Sofosbuvir and Velpatasvir and is a pan-genotypic direct antiviral drug (DAAs). Its significant advantage is that it is suitable for all 6 major genotypes of HCV, and there is no need to adjust the plan individually based on genotyping, which greatly simplifies the treatment process. More importantly, Epclusa’s broad-spectrum antiviral ability has been proven to have the potential to “functionally cure” hepatitis C.

The so-called "Functional cure" refers to the continuous undetectability of HCV viral RNA in the patient's body after completing the standard course of treatment, that is, "sustained virological response" (SVR), which is regarded as a clinical "cure" in the medical community. The general treatment course of Jisandai is 12 weeks. Once SVR12 is reached (virus negative 12 weeks after the end of treatment), the chance of recurrence is extremely low. Multiple studies and real-world applications around the world have shown that the cure rate of Epclusa is usually above 95%. In some special groups, such as patients without cirrhosis or newly treated patients, the rate is even higher.

Compared with traditional interferon combined with ribavirin therapy,Epclusa not only shortens the course of treatment and significantly reduces side effects, but also shows high efficacy in patients with cirrhosis or co-infection. Especially in the case of early interventional treatment, its treatment success rate is further improved.

However, although Jisandai can achieve a high rate of clinical cure, several key issues still need to be paid attention to. First of all, whether the patient adheres to the foot therapy course and takes medication on time directly determines the outcome of the treatment. Secondly, although the efficacy of drugs is powerful, it cannot prevent the risk of reinfection. Especially for high-risk behavioral groups, such as injection drug users and those who receive unsafe blood products, behavioral intervention and regular screening need to be strengthened.

In addition, hepatitis C patients should still undergo regular liver function monitoring after successful treatment. Especially for those with existing cirrhosis, their basic risk of liver cancer still needs to be managed. Epclusa’s function is to clear the virus, but it has no direct reversal effect on existing liver damage. If necessary, it should be combined with lifestyle adjustments and other liver protection measures.

Reference: https://www.epclusa.com/